Mary Devlin Capizzi

Mary Devlin Capizzi is a partner in the Government Relations & Regulatory Affairs Practice Group and is a member of the firm’s pharmaceutical practice. Mary counsels a broad range of domestic and international clients on corporate compliance, with an emphasis on regulatory, legislative and policy issues affecting the pharmaceutical industry. She serves as a managing partner of the firm, member and former chair of the firm’s Professional Development Committee.

Since 1998, Mary has represented industry groups and individual companies before the FDA and other regulatory bodies in the United States and Europe.  Mary’s practice includes serving as secretariat and legal counsel for several industry consortia addressing a range of compliance matters affecting the pharmaceutical and health care industry in the U.S., the EU, and other countries around the world.  She consults with clients on issues impacting research and commercial operations, including scientific and legal regulatory issues relating to drug product development, quality control and quality assurance, manufacturing, data privacy and data security challenges. Mary particularly enjoys facilitating industry-wide initiatives focused on addressing and resolving complex regulatory issues.

From 1994 to 1997, Mary worked in the Chicago office, where she focused on securities work and corporate compliance counseling for publicly traded companies.  Prior to joining the firm, she worked at Shearman & Sterling in New York as part of the team representing the bank advisory committee in negotiations with the Brazilian government on the restructuring of its sovereign external debt.

In General.  Mary is a graduate of Emory University School of Law and the University of Dallas Constantin College of Liberal Arts and Graduate School of Management.  She completed foreign study programs at L’Ecole des Cadres in Paris, France; La Universidad de San Luis in Madrid, Spain; Universidad Internacional, Center for Bilingual Multicultural Studies in Cuernavaca, Mexico; and Universitá di Dallas in Rome, Italy.  Mary is a member of the Drug Information Association, Food Drug and Law Institute, the Regulatory Affairs Professional Society and the Health Care Compliance Association.   Mary is a frequent speaker at pharmaceutical and health care conferences.  She also serves as a member of the BNA Pharmaceutical Law & Industry Report Advisory Board.

Mary lives with her husband, Joseph, and children in Chevy Chase, Maryland.  In addition to spending time with her family, she enjoys photography, running, reading, and telling and writing children’s stories.

Ask Mary a Question



From the Blog

Louisiana Supreme Court Strikes Down Expansive Interpretation of State Medicaid Fraud Statute

In a decision that has important ramifications for the life sciences industry, on January 28, 2013, in Caldwell ex rel State of Louisiana v....

FTC Amendments to Premerger Notification Rules: The Who, What & Why

On November 6, 2013, the Federal Trade Commission released final amendments to the Hart-Scott-Rodino Premerger Notification Rules to clarify when a transaction involving the transfer of...

The Debate Over Mobile Health Software Regulation

On November 19th, the House Energy and Commerce Subcommittee on Health held a hearing to examine the federal regulation of mobile medical applications (mobile...